Development of Tumor Organoids from Undifferentiated Primary Carcinomas to Guide Therapeutic Decisions
Not Applicable
Not yet recruiting
- Conditions
- Undifferentiated Carcinoma
- Interventions
- Other: organoid etablishment
- Registration Number
- NCT06612827
- Lead Sponsor
- Centre Francois Baclesse
- Brief Summary
The study is based on the constitution of a collection of tumor and blood samples for the development of tumoroid for functional tests to predict clinical response to treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 15
Inclusion Criteria
- Patient with undifferentiated primary carcinoma (UPC) with histological and immunohistochemical evidence, validated in a local and/or national UPC multidisciplinary consultation
- Patient with indication for 1st-line treatment at the time of inclusion.
- Patient with life expectancy greater than 3 months
- Patient of legal age
- Patient affiliated to a social security scheme
- Signature of informed consent prior to any specific study procedure
Exclusion Criteria
- Persons deprived of their liberty or under guardianship (including curatorship)
- Pregnant or breast-feeding patient
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Blood and tumor collection organoid etablishment Blood and tumor collection before treatment initiation
- Primary Outcome Measures
Name Time Method Rate of establishment of exploitable tumor organoids through study completion, an average of 3 years Rate of establishment usable tumor organoids for predictive tests of response to treatment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Centre François Baclesse
🇫🇷Caen, France